Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$0.25
-7.3%
$4.79
$4.86
$37.50
$1.52M1.55467,323 shs3.23 million shs
Digirad Co. stock logo
DRAD
Digirad
$0.90
-2.2%
$3.58
$1.99
$8.84
$4.30M0.18485,592 shs22,392 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$0.30
$0.58
$0.22
$2.79
$3.56M1.13122,853 shs30,324 shs
NIMU
Non-Invasive Monitoring Systems
$0.01
$0.01
$0.00
$0.04
$1.83M0.68195 shsN/A
Vaso Co. stock logo
VASO
Vaso
$0.26
$0.29
$0.19
$0.37
$47.69M2.11112,781 shs191,355 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nuwellis, Inc. stock logo
CHFS
Nuwellis
+4.21%+106.39%-28.61%-39.93%-91.45%
Digirad Co. stock logo
DRAD
Digirad
-0.96%+0.64%+0.10%-3.62%+3.88%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-6.31%-8.83%-15.96%-74.56%-77.74%
NIMU
Non-Invasive Monitoring Systems
0.00%-1.67%0.00%+5,800.00%-30.59%
Vaso Co. stock logo
VASO
Vaso
-2.44%-4.83%-9.83%-20.19%+9.32%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
N/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$5.51M0.28N/AN/A$12.79 per share0.02
Digirad Co. stock logo
DRAD
Digirad
$114.18M0.04$1.31 per share0.69$10.30 per share0.09
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$0.67 per shareN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
$81.02M0.59$0.03 per share8.39$0.14 per share1.83

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/A
Digirad Co. stock logo
DRAD
Digirad
-$4.63M-$0.35N/AN/A-5.32%-3.75%-0.85%N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$10.06M-$1.93N/AN/AN/A-197.36%-144.22%5/14/2024 (Confirmed)
NIMU
Non-Invasive Monitoring Systems
-$200KN/A0.00N/AN/AN/A-251.56%N/A
Vaso Co. stock logo
VASO
Vaso
$4.80M$0.038.57N/A5.93%19.02%6.59%5/13/2024 (Estimated)

Latest NDRA, DRAD, VASO, NIMU, and CHFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/AN/A
4/1/2024Q4 2023
Vaso Co. stock logo
VASO
Vaso
N/A$0.01+$0.01$0.01N/A$21.92 million
3/28/2024Q4 2023
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A-$0.17-$0.17-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/A
Digirad Co. stock logo
DRAD
Digirad
$2.20243.31%N/AN/A N/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/A
Vaso Co. stock logo
VASO
Vaso
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/A
6.87
5.97
Digirad Co. stock logo
DRAD
Digirad
0.88
1.27
0.91
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
6.26
3.36
NIMU
Non-Invasive Monitoring Systems
N/A
0.36
0.36
Vaso Co. stock logo
VASO
Vaso
N/A
1.50
1.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
65.06%
Digirad Co. stock logo
DRAD
Digirad
11.38%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%
NIMU
Non-Invasive Monitoring Systems
0.12%
Vaso Co. stock logo
VASO
Vaso
N/A

Insider Ownership

CompanyInsider Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
0.60%
Digirad Co. stock logo
DRAD
Digirad
12.49%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
4.80%
NIMU
Non-Invasive Monitoring Systems
28.80%
Vaso Co. stock logo
VASO
Vaso
44.56%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Nuwellis, Inc. stock logo
CHFS
Nuwellis
666.04 millionN/ANot Optionable
Digirad Co. stock logo
DRAD
Digirad
6184.76 millionN/ANot Optionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2111.04 million10.51 millionNot Optionable
NIMU
Non-Invasive Monitoring Systems
3N/AN/ANot Optionable
Vaso Co. stock logo
VASO
Vaso
300185.63 million102.91 millionNot Optionable

NDRA, DRAD, VASO, NIMU, and CHFS Headlines

SourceHeadline
SCD Birth Rate Higher in Socially Vulnerable Areas, Study FindsSCD Birth Rate Higher in Socially Vulnerable Areas, Study Finds
ajmc.com - May 9 at 12:58 PM
2016 CDC Opioid Guideline Led to Unintended Vascular Consequences in Patients With Sickle Cell Disease2016 CDC Opioid Guideline Led to Unintended Vascular Consequences in Patients With Sickle Cell Disease
thecardiologyadvisor.com - May 8 at 3:54 PM
bluebird bio completes first commercial cell collection for Lyfgenia gene therapybluebird bio completes first commercial cell collection for Lyfgenia gene therapy
pharmabiz.com - May 7 at 7:45 AM
Following Roe v Wade Overturn, Research Focuses on Male ContraceptivesFollowing Roe v Wade Overturn, Research Focuses on Male Contraceptives
ajmc.com - May 6 at 4:41 PM
Hydroxyurea dose escalation enhances clinical outcomes in children with sickle cell anemia: StudyHydroxyurea dose escalation enhances clinical outcomes in children with sickle cell anemia: Study
medicaldialogues.in - May 5 at 4:47 PM
A bleed apart: Why even 300 stitches can’t stop Cronulla’s hard manA bleed apart: Why even 300 stitches can’t stop Cronulla’s hard man
msn.com - May 4 at 4:29 AM
SMT and HeartX Forge Transformative Partnership in Cardiovascular SpaceSMT and HeartX Forge Transformative Partnership in Cardiovascular Space
businesswireindia.com - May 3 at 1:21 AM
This pre-workout supplement is best for evening workouts – and it has 40% offThis pre-workout supplement is best for evening workouts – and it has 40% off
msn.com - May 2 at 10:04 AM
Mother’s Day 2024 Brunch: Where To Take Mom Out In AlexandriaMother’s Day 2024 Brunch: Where To Take Mom Out In Alexandria
msn.com - May 2 at 12:17 AM
Corn in a CupCorn in a Cup
msn.com - May 1 at 9:15 AM
Real Madrid: Ancelotti se disculpa por su alemán previo al encuentro ante BayernReal Madrid: Ancelotti se disculpa por su alemán previo al encuentro ante Bayern
msn.com - April 29 at 10:12 PM
The Best Places For Lunch Dates In Río PiedrasThe Best Places For Lunch Dates In Río Piedras
hercampus.com - April 29 at 5:12 PM
Sickle Cell and uplifting energy levelsSickle Cell and uplifting energy levels
msn.com - April 27 at 1:04 PM
Charleston man died after being beaten, pepper sprayed by prison guards. Feds opt to settle.Charleston man died after being beaten, pepper sprayed by prison guards. Feds opt to settle.
postandcourier.com - April 27 at 1:04 PM
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of bluebird bioSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of bluebird bio
markets.businessinsider.com - April 26 at 8:11 AM
Exa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell PatientsExa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell Patients
physiciansweekly.com - April 26 at 3:09 AM
Justice department to pay 700K to estate of Charleston man who died in federal prisonJustice department to pay 700K to estate of Charleston man who died in federal prison
msn.com - April 25 at 10:08 PM
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patientsCASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients
news-medical.net - April 25 at 12:04 PM
How can I cut down on food waste?How can I cut down on food waste?
unr.edu - April 24 at 3:27 PM
Greek lawmaker faces criminal charges after brawl in parliamentGreek lawmaker faces criminal charges after brawl in parliament
politico.eu - April 24 at 3:27 PM
Alteration of brain network condition could predict painful vaso-occlusive crisis in patients with sickle cell diseaseAlteration of brain network condition could predict painful vaso-occlusive crisis in patients with sickle cell disease
medicalxpress.com - April 24 at 3:27 PM
Greece arrests suspected members of criminal group linked to sports violenceGreece arrests suspected members of criminal group linked to sports violence
devdiscourse.com - April 23 at 3:26 PM
Greek police arrest 63 people in football hooligan crackdown after string of murdersGreek police arrest 63 people in football hooligan crackdown after string of murders
independent.co.uk - April 23 at 3:26 PM
Profluent combines LLMs and CRISPR for open-source gene editing projectProfluent combines LLMs and CRISPR for open-source gene editing project
fiercebiotech.com - April 23 at 3:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis logo

Nuwellis

NASDAQ:CHFS
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Digirad logo

Digirad

NASDAQ:DRAD
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Construction, and Real Estate and Investments. The company offers imaging and monitoring services to healthcare providers; and contract diagnostic imaging, including computerized tomography (CT), magnetic resonance imaging, positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. It also develops, sells, and maintains solid-state gamma cameras, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; and manages real estate assets and investments. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia.
ENDRA Life Sciences logo

ENDRA Life Sciences

NASDAQ:NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Non-Invasive Monitoring Systems

OTCMKTS:NIMU
Non-Invasive Monitoring Systems, Inc. does not have significant operations. Previously, it was involved in the research, development, manufacture, marketing, and sale of non-invasive, motorized, and whole body periodic acceleration platforms. The company was incorporated in 1980 and is based in Miami, Florida.
Vaso logo

Vaso

OTCMKTS:VASO
Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.